Last reviewed · How we verify
Pentapiperium — Competitive Intelligence Brief
unknown
Dermatology
Live · refreshed every 30 min
Target snapshot
Pentapiperium (pentapiperium metilsulfate). Pentapiperium works by inhibiting the action of histamine on the stomach lining, reducing acid production and promoting healing of peptic ulcers.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pentapiperium TARGET | pentapiperium metilsulfate | unknown |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pentapiperium CI watch — RSS
- Pentapiperium CI watch — Atom
- Pentapiperium CI watch — JSON
- Pentapiperium alone — RSS
Cite this brief
Drug Landscape (2026). Pentapiperium — Competitive Intelligence Brief. https://druglandscape.com/ci/pentapiperium-metilsulfate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing